Paper Details

  1. Home
  2. Paper Details

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Author: BramhallSimon R, BuckelsJohn A C, HassanA Bassim, HewittHelen, JohnsonPhilip J, MarkhamCatherine E, PalmerDaniel H, StockenDeborah D

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Survival rates for people with pancreatic cancer after surgery are still low, but giving chemotherapy after surgery (adjuvant) improves outcomes. However, many patients don't receive all their prescribed chemotherapy. Giving chemotherapy before surgery (neoadjuvant) might improve treatment completion rates, shrink tumors before surgery, and potentially kill microscopic cancer cells that have spread. This study compared different chemotherapy regimens that include gemcitabine to identify the most promising treatment for future research on neoadjuvant therapy.
Paper Details　
Original Abstract of the Article :
Survival after surgery for pancreas cancer remains low. This improves with adjuvant chemotherapy, but up to 30% patients do not receive the prescribed treatment. Neoadjuvant therapy may increase the proportion of patients who receive all treatment components, may downstage disease before surgery, an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1245/s10434-007-9384-x

データ提供：米国国立医学図書館（NLM）

Neoadjuvant Chemotherapy for Pancreatic Cancer: A Quest for a New Oasis in the Desert of Treatment

We're venturing deep into the often-treacherous desert of pancreatic cancer, a disease characterized by its aggressive nature and limited treatment options. This randomized phase 2 trial, like a team of researchers braving the dunes, aimed to investigate the potential of neoadjuvant chemotherapy, a strategy of administering chemotherapy before surgery, to improve outcomes for patients with resectable pancreatic cancer.

Neoadjuvant Chemotherapy: A Potential Oasis in the Desert of Pancreatic Cancer Treatment?

The researchers compared two gemcitabine-based chemotherapy regimens, seeking to identify the most effective approach, a hidden spring of hope, for patients with resectable pancreatic cancer. While the study provided promising preliminary results, it emphasized the need for further research to confirm the effectiveness and optimize the use of neoadjuvant chemotherapy in this challenging disease.

Navigating the Desert of Pancreatic Cancer Treatment with Innovation

This research, like a map guiding us through the desert, highlights the ongoing search for new and effective treatment options for pancreatic cancer. The study underscores the importance of exploring innovative approaches like neoadjuvant chemotherapy, with the goal of improving patient outcomes and offering a greater chance of survival.

Dr.Camel's Conclusion

The desert of pancreatic cancer treatment can be a daunting landscape, but this research offers a glimmer of hope. Neoadjuvant chemotherapy, like finding a new oasis in the desert, may hold promise for improving outcomes for patients with resectable pancreatic cancer. Further research is crucial to refine this approach and ensure its effectiveness and safety. As we continue our journey through the desert of pancreatic cancer treatment, innovation and perseverance remain essential.

Date :
  1. Date Completed 2007-10-23
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

17453298

DOI: Digital Object Identifier

10.1245/s10434-007-9384-x

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.